BC
HRTX icon

Bridgefront Capital’s Heron Therapeutics HRTX Stock Holding History

Bridgefront Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,493
Closed -$60K – 361
2022
Q1 		$60K Buy
+10,493
New +$76.8K 0.07% 247

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bridgefront Capital's HRTX Position: Q2 2022 in Review

Bridgefront Capital sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 10,493 shares — an estimated $60K sold.

Bridgefront Capital first reported a position in HRTX in Q1 2022 and held it in 1 quarter. The position peaked at $60K in Q1 2022. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • Bridgefront Capital reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bridgefront Capital sold 10,493 Heron Therapeutics shares in Q2 2022, an estimated $60K.
  • Bridgefront Capital first reported a position in Heron Therapeutics in Q1 2022 and held it in 1 quarter.
  • Bridgefront Capital's Heron Therapeutics position peaked at $60K in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Bridgefront Capital's 13F filing for Q2 2022, filed 12 Aug 2022.